American journal of translational research最新文献

{"title":"Risk factors and interventions for post-percutaneous nephrolithotomy urinary tract infection in diabetic patients with renal calculi.","authors":"Jinbiao Zhou, Xiaqing Shen, Licheng Cai, Weiwei Qi","doi":"10.62347/KPKW8743","DOIUrl":"10.62347/KPKW8743","url":null,"abstract":"<p><strong>Objective: </strong>To investigate risk factors and interventions for post-percutaneous nephrolithotomy (PCNL) urinary tract infection (UTI) in patients with renal calculi and diabetes mellitus (DM).</p><p><strong>Methods: </strong>Clinical data of 210 DM patients with renal calculi who underwent PCNL at Hu Zhou Central Hospital between January 2018 and October 2024 were retrospectively analyzed. Patients were divided into infection and non-infection groups based on post-PCNL UTI occurrence. Univariate and multivariate logistic regression analyses was performed to identify risk factors. Negative emotions (Self-Rating Anxiety/Depression Scale [SAS]/[SDS]), pain intensity (Visual Analogue Scale [VAS]), sleep quality (Pittsburgh Sleep Quality Index [PSQI]), and quality of life level (Short-Form 36-Item Health Survey [SF-36]) were also assessed.</p><p><strong>Results: </strong>Among the 210 patients, 33 (15.71%) developed post-PCNL UTI, with 27 (67.50%) Gram-negative bacterial strains identified. Univariate analysis revealed that age, operation time (OT), number of renal calculi, fasting blood glucose (FBG), and preoperative UTI were significantly associated with post-PCNL UTI. Multivariate analysis identified age ≥60 years (P=0.001), OT ≥90 min (P=0.031), FBG ≥10 mmol/L (P<0.001), and preoperative UTI (P=0.013) as independent risk factors. Patients with UTI exhibited significantly higher SAS, SDS, VAS, and PSQI scores, along with lower SF-36 scores compared to non-infected patients.</p><p><strong>Conclusions: </strong>Age ≥60 years, OT ≥90 min, FBG ≥10 mmol/L, and preoperative UTI are risk factors for post-PCNL UTI. Patients with these risk factors require enhanced perioperative nursing and targeted preventive measures. Furthermore, tailored interventions should be implemented to address their negative emotions, pain, sleep quality, and quality of life.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"6462-6469"},"PeriodicalIF":1.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of celecoxib combined with glucosamine hydrochloride in the management of knee osteoarthritis.","authors":"Lv Cheng, Guang-Zheng Li, Xiang Shen, Yang Xie","doi":"10.62347/AHTO9889","DOIUrl":"10.62347/AHTO9889","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical efficacy of combination therapy with celecoxib (CEL) and glucosamine hydrochloride (GH) in patients with knee osteoarthritis (KOA).</p><p><strong>Methods: </strong>A total of 115 KOA patients were retrospectively analyzed and divided into a research group that received CEL combined with GH (n=62), while the control group received CEL alone (n=53). Clinical outcomes, safety, pain severity, knee joint function, quality of life (QoL), bone metabolic markers, and inflammatory indicators were assessed and compared between the groups. Factors associated with treatment efficacy were also analyzed.</p><p><strong>Results: </strong>The research group showed a significantly higher overall response rate (P=0.018), with no increase in adverse events (P>0.05). Compared to the control group, patients receiving combination therapy experienced greater improvements in pain relief, joint function, QoL, and bone metabolism, along with a more pronounced reduction in inflammatory markers (all P<0.05). Multivariate analysis identified advanced age, alcohol consumption, and smoking history as independent risk factors for poor therapeutic response (all P<0.05).</p><p><strong>Conclusions: </strong>Combination therapy with CEL and GH provides superior clinical benefits for KOA management. However, its efficacy may be reduced in older patients and those with a history of alcohol use or smoking.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"6359-6369"},"PeriodicalIF":1.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of β-lactam/β-lactamase inhibitor combinations in multidrug-resistant bacterial infections: a comprehensive meta-analysis.","authors":"Fei Wu, Qiaoli Liu, Piao Hu, Changcai Wu","doi":"10.62347/JVJW7760","DOIUrl":"10.62347/JVJW7760","url":null,"abstract":"<p><strong>Background: </strong>Multidrug-resistant (MDR) bacterial infections pose a global public health challenge. β-Lactam/β-lactamase inhibitor combinations (BLIs) are essential for treating MDR infections, although their efficacy varies across studies. This meta-analysis aims to evaluate their clinical value.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, and Cochrane Library was conducted for randomized controlled trials (RCTs) on BLIs for MDR bacterial infections published from January 2000 to December 2024. Study quality was assessed using the Cochrane Risk of Bias tool, and meta-analysis was performed using RevMan 5.4. Primary outcomes included clinical efficacy rate, bacterial clearance rate, and incidence of adverse reactions.</p><p><strong>Results: </strong>Eighteen high-quality RCTs involving 2,356 patients were included. BLIs showed a significantly higher clinical efficacy rate (76.23%) than controls (62.45%) (RR=1.59, 95% CI: 1.44-1.73, P<0.001) and bacterial clearance rate (71.58% vs. 58.67%, RR=1.21, 95% CI: 1.16-1.26, P<0.001). Subgroup analysis revealed clinical efficacy rates of 73.45% for carbapenem-resistant Enterobacteriaceae (CRE) and 78.32% for ESBL-producing Enterobacteriaceae, with bacterial clearance rates of 68.72% and 74.11%, respectively. The adverse reaction rate in the BLI group was 15.68% (mainly diarrhea, nausea, rash), which was not significantly different from the control group (17.89%, RR=0.96, 95% CI: 0.85-1.07, P=0.977).</p><p><strong>Conclusion: </strong>BLIs demonstrate high efficacy, bacterial clearance, and safety in treating MDR infections, particularly CRE and ESBL infections. Larger multicenter RCTs are needed for further validation.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"6488-6503"},"PeriodicalIF":1.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy and prognostic analysis of autologous femoral head structural bone grafting combined with total hip arthroplasty for Crowe Type II/III developmental dysplasia of the hip in adults.","authors":"Chengyu Li, Fang Pei, Feng Wan, Baiyi Meng","doi":"10.62347/TUYG1784","DOIUrl":"10.62347/TUYG1784","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical efficacy and mid-term outcomes of total hip arthroplasty (THA) assisted by acetabular reconstruction using autologous femoral head structural bone grafting in patients with Crowe type II/III developmental dysplasia of the hip (DDH).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 100 patients (100 hips) with Crowe type II/III DDH who underwent THA at the Affiliated Hospital of Xuzhou Medical University between January 2019 and December 2022. All patients received autologous femoral head structural bone grafting for acetabular reconstruction during the procedure. Perioperative parameters, visual analogue scale (VAS) scores, limb length discrepancy (LLD), range of motion (ROM), hip function [Harris hip score and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)], incidence of complications, quality of life [Generic Quality of Life Inventory-74 (GQOLI-74)], and radiographic outcomes were assessed.</p><p><strong>Results: </strong>The mean follow-up duration was 10.78 ± 1.65 months. Postoperatively, the VAS score significantly decreased from 6.52 ± 2.58 to 1.73 ± 0.72 (P < 0.001), and the LLD reduced from 2.88 ± 0.54 cm to 0.92 ± 0.39 cm (P < 0.001). The Harris hip score increased from 58.23 ± 6.14 to 92.45 ± 5.82 (P < 0.001), while the WOMAC score decreased from 72.54 ± 8.61 to 18.34 ± 5.09 (P < 0.001). All domains of the GQOLI-74 score showed significant improvements (P < 0.001). The overall complication rate was 1.0%, and radiographic assessments confirmed bone healing.</p><p><strong>Conclusion: </strong>THA assisted by autologous femoral head structural bone grafting is a safe and effective approach for treating Crowe type II/III DDH. It significantly enhances hip function, restores biomechanics, improves the quality of life, and is associated with a low complication rate and favorable mid-term outcomes.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"5987-5998"},"PeriodicalIF":1.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of orthodontic treatment on periodontal health and masticatory function in patients with anterior teeth displacement due to periodontal disease.","authors":"Bingkun Jiang, Mengxi Wang, Minjie Wang","doi":"10.62347/IFFB7880","DOIUrl":"10.62347/IFFB7880","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the combined effect of orthodontic treatment and periodontal care on improving periodontal health and masticatory function in patients with anterior teeth displacement caused by periodontal disease.</p><p><strong>Methods: </strong>This retrospective study involved 200 patients with anterior teeth displacement due to periodontal disease, treated between January 2022 and January 2025. Patients were divided into a control group (n=103), receiving standard periodontal treatment, and an observation group (n=97), receiving combined periodontal and orthodontic treatment. Clinical measurements, including probing depth (PD), clinical attachment level (CAL), gingival bleeding index (GBI), occlusal force, and chewing efficiency, were taken before, after treatment, and during a 12-month follow-up. Paired t-tests and regression models compared the outcomes.</p><p><strong>Results: </strong>The observation group showed significant improvement in periodontal health compared to the control group (P>0.05). Post-treatment, CAL, GBI and PD decreased significantly (all P<0.001). Masticatory function, including occlusal force and chewing efficiency, improved significantly in the observation group (P<0.001). The overall effective rate was higher in the observation group (96.91%) compared to the control group (74.75%) (P=0.017). Additionally, pain levels, measured by visual analog scale (VAS), were lower in the observation group (P<0.001). Incidence of dental diseases, including gingival bleeding and periodontal abscess, was also significantly lower (P<0.001). Multivariate analysis identified orthodontic treatment (OR: 2.883, 95% CI: 2.183-3.799, P<0.001) as a significant contributor to clinical efficacy.</p><p><strong>Conclusion: </strong>The combination of orthodontic treatment and periodontal care significantly enhances periodontal health, masticatory function, and reduces dental complications in patients with anterior teeth displacement due to periodontal disease.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"6470-6480"},"PeriodicalIF":1.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive evaluation of combined AngioJet and drug-coated balloon therapy for diabetic foot ulcers with lower extremity arterial occlusive disease.","authors":"Binyu Zhao, Xiaobin Yang, Jinquan Jiang, Qiqi Xu, Bo Li","doi":"10.62347/CDFB3086","DOIUrl":"10.62347/CDFB3086","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy of AngioJet mechanical thrombectomy combined with drug-coated balloon (DCB) therapy in patients with lower extremity arterial occlusive disease (ASO) and diabetic foot ulcers (DFU), focusing on its effects on hemodynamics, glycemic control, inflammatory markers, and one-year ulcer recurrence.</p><p><strong>Methods: </strong>This retrospective study involved 198 patients with ASO and DFU treated between April 2021 and March 2024. Of these, 104 received combined AngioJet and DCB therapy (combined group), while 94 underwent mechanical thrombectomy alone (control group). Clinical outcomes, hemodynamic parameters, blood glucose levels, inflammatory markers, and functional scores were assessed before and after treatment. Ulcer recurrence was evaluated during a one-year follow-up period.</p><p><strong>Results: </strong>The combined group exhibited significantly better clinical outcomes and greater improvements in hemodynamics (pulse index and resistive index), glycemic control (fasting/postprandial glucose and HbA1c), and inflammatory markers (CRP, TNF-α, IL-6) compared to the control group. Functional indicators, including the ankle-brachial index, Rutherford and Wagner grades, and claudication distance, improved more in the combined group. The one-year recurrence rate was significantly lower in the combined group.</p><p><strong>Conclusion: </strong>The combined AngioJet-DCB approach demonstrates enhanced clinical efficacy in the management of ASO-DFU by improving hemodynamic outcomes and reducing the risk of ulcer recurrence.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"6166-6179"},"PeriodicalIF":1.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Danqi soft capsules alleviate myocardial ischemia/reperfusion injury through inhibiting apoptosis-related signaling pathways.","authors":"Qian Song, Ye Yang, Sai Hao, Xiaoyu Qiang, Keqiang He, Jin Ma","doi":"10.62347/DODM6651","DOIUrl":"10.62347/DODM6651","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the mechanisms of Danqi Soft Capsules (DQ) in reducing myocardial ischemia/reperfusion injury (MI/RI) through network pharmacology, molecular docking, and experimental validation.</p><p><strong>Methods: </strong>The TCMSP database was used to screen for active ingredients of DQ and their potential targets, and compare them to MI/RI-related targets to construct a \"drug-active ingredient-target\" network. The protein-protein interaction (PPI) network was constructed using the STRING database; and Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed. Molecular docking experiments verified the binding affinity between DQ's active ingredients and apoptosis-related target proteins, and cellular experiments validated DQ's anti-apoptotic effects in the H9c2 cardiomyocyte hypoxia/reoxygenation model.</p><p><strong>Results: </strong>Network pharmacology analysis identified 66 active ingredients and 240 potential targets, of which 105 were related to MI/RI. PPI network analysis screened out 10 core targets. GO and KEGG analyses indicated that these targets were related to the pathways of cell apoptosis. The molecular docking experiment confirmed that the active ingredient had a strong binding affinity with the core target, with the binding affinity between tumor necrosis factor (TNF) and tanshinone IIA being -9.2 kcal/mol, and that between tumor protein (TP) 53 and quercetin being -8.6 kcal/mol. Cellular experimental results showed that the cell apoptosis rate in the DQ-treated group was lower than in the model group, with the protective effect in the high-dose group being slightly better than the low-dose group.</p><p><strong>Conclusion: </strong>This study revealed that DQ alleviates MI/RI by inhibiting cell apoptosis, providing a scientific basis for the clinical application of DQ and offering new directions for drug development.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"6587-6600"},"PeriodicalIF":1.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artemether ameliorates type 1 diabetes mellitus by modulating glycolipid metabolism in skeletal muscle.","authors":"Yifan Dong, Qike Fu, Yating Zhang, Wenci Weng, Pengxun Han, Yuchun Cai, Huili Sun","doi":"10.62347/DEHS8462","DOIUrl":"10.62347/DEHS8462","url":null,"abstract":"<p><p>Diabetes is a metabolic disorder involving disruptions in glucose and lipid homeostasis. Skeletal muscle, the primary organ responsible for insulin responsiveness, is crucial for regulating glucose and lipid metabolism. Modulating glucose and lipid metabolism within skeletal muscle to treat diabetes remains an active research area. Artemether, an anti-malarial agent, has significant anti-diabetic and lipid-lowering effects. A type 1 diabetes (T1D) mouse model was induced using streptozotocin. This study comprised three groups: wild-type controls, T1D mice, and T1D mice that received artemether for 8 weeks. Hypoglycemic efficacy was assessed by measuring fasting blood glucose and glycated hemoglobin A1c. Muscle fiber characteristics were analyzed using periodic acid-Schiff staining and immunofluorescence. Alterations in glucose, lipid, pyruvate, and fatty acid metabolism in skeletal muscle were analyzed using immunoblotting, immunofluorescence, and qPCR. In T1D mice, glucose glycolysis and pyruvate metabolism were impaired, whereas fatty acid uptake and use were enhanced. Artemether treatment inhibited pyruvate dehydrogenase kinase 4 activity and activated pyruvate dehydrogenase, promoting aerobic glucose metabolism and suppressing fatty acid metabolism in skeletal muscle. These findings suggest that artemether can alleviate symptoms in T1D mice by modulating glycolipid metabolism in skeletal muscle.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"5871-5884"},"PeriodicalIF":1.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amiodarone combined with metoprolol improves cardiac function in patients with coronary heart disease complicated by arrhythmia.","authors":"Xiaolei Fu, Qiuping Xie, Chengming Wang, Xin Yan, Zhixiong Wu, Xiong Liu, Hui Zhang","doi":"10.62347/TTLB6414","DOIUrl":"10.62347/TTLB6414","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of amiodarone combined with metoprolol for improving cardiac function in patients with coronary heart disease (CHD) complicated by arrhythmia.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 102 patients with CHD and arrhythmia treated at Zhuzhou Central Hospital from January 2018 to March 2021. Patients were divided into two groups: an amiodarone group (n = 48) and a combination group (amiodarone plus metoprolol, n = 54). Primary endpoints included therapeutic efficacy, time to clinical stability and cardioversion, QT dispersion (QTd), heart rate, hemodynamic indices (plasma fibrinogen, hematocrit, plasma viscosity), cardiac function indices (LVEDD, LVEF, LVESD), heart rate variability (HRV) indices (premature contractions, SDNN, SDNNI), myocardial biomarkers, and adverse events. Cardiovascular event rates were also compared using a 3-year follow-up.</p><p><strong>Results: </strong>The combination group showed a significantly higher efficacy rate (P<0.05), with faster clinical stabilization and cardioversion (P<0.05). Both groups improved post-treatment, but the combination group showed greater improvements in QTd, heart rate, hemodynamics, cardiac function, HRV indices, and myocardial markers (all P<0.05). Adverse events were significantly lower in the combination group (P<0.001), as was the incidence of cardiovascular events during follow-up (P<0.05).</p><p><strong>Conclusion: </strong>Amiodarone combined with metoprolol is a safe and effective strategy for managing CHD complicated by arrhythmia, providing superior improvements in cardiac function and HRV, with a lower rate of adverse events.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"6131-6140"},"PeriodicalIF":1.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DUSP1 alleviates LPS-induced acute lung injury by inhibiting the SHP2-JNK axis and mitochondrial apoptosis.","authors":"Sheng Chen, Yunnan Hu, Lingfeng Li, Jiaxin Zhang, Rongda Huang, Mirong Tang","doi":"10.62347/QAUM4023","DOIUrl":"10.62347/QAUM4023","url":null,"abstract":"<p><strong>Background: </strong>Lipopolysaccharide (LPS) induces acute lung injury (ALI), a condition characterized by oxidative stress, inflammation, and apoptosis, ultimately leading to respiratory failure. Dual-specificity phosphatase 1 (DUSP1), a key regulator of MAPK signaling, may offer protection against inflammatory damage.</p><p><strong>Objective: </strong>This study aimed to investigate the protective effects of DUSP1 overexpression against LPS-induced inflammatory injury and to explore the underlying molecular mechanisms using both <i>in vitro</i> and <i>in vivo</i> models.</p><p><strong>Methods: </strong>Cellular and murine ALI models were established using LPS. DUSP1 was overexpressed via plasmid transfection for <i>in vitro</i> experiments and viral vectors for <i>in vivo</i> studies. Cell viability, apoptosis, reactive oxygen species (ROS), and pro-inflammatory cytokine levels (IL-1β, IL-6, TNF-α) were assessed. In mice, lung injury was evaluated through bronchoalveolar lavage fluid (BALF) analysis, lung mechanics, and histopathology. DUSP1-SHP2 interactions were predicted using bioinformatics and validated through co-immunoprecipitation. JNK pathway activation was analyzed by Western blotting, and dual-luciferase reporter assays confirmed the regulatory interaction between DUSP1 and SHP2.</p><p><strong>Results: </strong>In vitro, DUSP1 overexpression significantly enhanced cell viability while reducing apoptosis, ROS, malondialdehyde (MDA), and inflammatory cytokines in LPS-stimulated cells. In vivo, DUSP1 overexpression substantially alleviated LPS-induced lung injury, evidenced by decreased BALF protein, reduced lung water content, lower airway resistance, improved pulmonary function, and less tissue damage. Mechanistically, DUSP1 directly interacted with SHP2, inhibiting its phosphorylation, which in turn suppressed the phosphorylation of p53 and JNK. DUSP1 overexpression also downregulated PINK1/Parkin-mediated mitophagy, key pro-apoptotic proteins (Cytochrome C, Caspase-3, Bax), and the NLRP3 inflammasome. Anisomycin treatment reversed these protective effects, confirming the dependence of DUSP1's protective action on JNK pathway inhibition.</p><p><strong>Conclusion: </strong>DUSP1 overexpression alleviates LPS-induced lung inflammation and injury by targeting the SHP2-JNK axis and restoring mitochondrial homeostasis. These findings position DUSP1 as a promising therapeutic target for inflammatory lung disorders.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 8","pages":"6414-6424"},"PeriodicalIF":1.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}